Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgical Pathology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The 2017 bethesda system for reporting thyroid cytopathology.J Am Soc Cytopathol. 2017; 6: 217-222
- Pitfalls in thyroid cytopathology.Surg Pathol Clin. 2019; 12: 865-881
- Macrofollicular variant follicular thyroid tumors are DICER1 mutated and exhibit distinct histological features.Histopathology. 2021; 79: 661-666
- Macrofollicular variant of papillary carcinoma, a potential diagnostic pitfall: a report of two cases including a review of literature.Cytojournal. 2013; 10: 16
- Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.Cancer. 2018; 124: 1682-1690
- Benign call rate and molecular test result distribution of ThyroSeq v3.Cancer Cytopathol. 2019; 127: 161-168
- Update on molecular testing for cytologically indeterminate thyroid nodules.Adv Anat Pathol. 2019; 26: 114-123
- The bethesda system for reporting thyroid cytopathology: a meta-analysis.Acta Cytol. 2012; 56: 333-339
- Role of ancillary techniques in thyroid cytology specimens.Acta Cytol. 2020; 64: 40-51
- Update on molecular testing for cytologically indeterminate thyroid nodules.Arch Pathol Lab Med. 2018; 142: 446-457
- Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.Cytopathology. 2017; 28: 65-73
- Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).Thyroid. 2014; 24: 832-839
- Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance.Am J Clin Pathol. 2011; 136: 572-577
- Diagnostic performances of the afirma gene sequencing classifier in comparison with the gene expression classifier: a meta-analysis.Cancer Cytopathol. 2021; 129: 182-189
- Identification of parathyroid tissue in thyroid fine-needle aspiration: A combined approach using cytology, immunohistochemical, and molecular methods.Diagn Cytopathol. 2017; 45: 526-532
- Parathyroid cytology: avoiding diagnostic pitfalls.Head Neck. 2002; 24: 157-164
- Application of GATA 3 and TTF-1 in differentiating parathyroid and thyroid nodules on cytology specimens.Diagn Cytopathol. 2020; 48: 128-137
- Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids.Clin Chem Lab Med. 2017; 55: 914-925
- Cyto-morphological features of parathyroid lesions: Fine-needle aspiration cytology series from an endocrine tumor referral center.Diagn Cytopathol. 2022; 50: 75-83
- Distinguishing parathyroid and thyroid lesions on ultrasound-guided fine-needle aspiration: A correlation of clinical data, ancillary studies, and molecular analysis.Cancer Cytopathol. 2017; 125: 674-682
- Update on the cytologic and molecular features of medullary thyroid carcinoma.Adv Anat Pathol. 2014; 21: 26-35
- Fine needle aspiration cytology of medullary carcinoma of the thyroid with a focus on rare variants: a review of 78 cases.Cytopathology. 2011; 22: 95-105
- Cytologic diagnosis of medullary carcinoma of the thyroid gland.Diagn Cytopathol. 2000; 22: 351-358
- Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.Endocr J. 2017; 64: 1099-1104
- Insulinoma-associated protein 1 (INSM-1) expression in medullary thyroid carcinoma FNA: a multi-institutional study.J Am Soc Cytopathol. 2020; 9: 185-190
- The diagnostic utility of INSM1 and GATA3 in discriminating problematic medullary thyroid carcinoma, thyroid and parathyroid lesions.Pol J Pathol. 2021; 72: 11-22
- Thyroglobulin in medullary thyroid carcinoma: immunohistochemical study with polyclonal and monoclonal antibodies.Hum Pathol. 1993; 24: 256-262
- Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study.Clin Endocrinol (Oxf). 2014; 80: 135-140
- Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.J Clin Endocrinol Metab. 2013; 98: E1852-E1860
- Impact of the multi-gene thyroseq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology.Thyroid. 2015; 25: 1217-1223
- Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests.Thyroid. 2013; 23: 308-316
- Hyalinizing trabecular tumor: cytologic, histologic and molecular features and diagnostic considerations.Ann Diagn Pathol. 2021; 54: 151803
- GLIS rearrangements in thyroid nodules: a key to preoperative diagnosis of hyalinizing trabecular tumor.Cancer Cytopathol. 2019; 127: 560-566
- Macrofollicular variant of follicular thyroid carcinoma: a rare underappreciated pitfall in the diagnosis of thyroid carcinoma.Thyroid. 2020; 30: 72-80
- Integrated genomic characterization of papillary thyroid carcinoma.Cell. 2014; 159: 676-690
- Correlation of thyroseq results with surgical histopathology in cytologically indeterminate thyroid nodules.Endocr Pathol. 2020; 31: 377-384
- TERT promoter mutations in thyroid cancer.Endocr Relat Cancer. 2016; 23: R143-R155
- Genomic characterization of differentiated thyroid carcinoma.Endocrinol Metab (Seoul). 2019; 34: 1-10
- A decade into thyroid molecular testing: where do we stand?.J Am Soc Cytopathol. 2022; 11: 59-61
- The role of the thyroSeq v3 molecular test in the surgical management of thyroid nodules in the canadian public health care setting.Thyroid. 2020; 30: 1280-1287
- Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.Cancer. 2014; 120: 3627-3634
- Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: an institutional experience.Diagn Cytopathol. 2021; 49: 921-927
- Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules.JAMA Surg. 2018; 153: 817-824
- The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision-making from a fine-needle aspiration sample.Cancer Cytopathol. 2020; 128: 452-459
- Limitations of detecting genetic variants from the RNA sequencing data in tissue and fine-needle aspiration samples.Thyroid. 2021; 31: 589-595
- Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules.J Am Soc Cytopathol. 2020; 9: 232-241
- Thyroseq v3, Afirma GSC, and microRNA panels versus previous molecular tests in the preoperative diagnosis of indeterminate thyroid nodules: a systematic review and meta-analysis.Front Endocrinol (Lausanne). 2021; 12: 649522
- Multiplatform molecular test performance in indeterminate thyroid nodules.Diagn Cytopathol. 2020; 48: 1254-1264
- Kinase fusion-related thyroid carcinomas: distinct pathologic entities with evolving diagnostic implications.Diagn Histopathol (Oxf). 2021; 27: 252-262
- Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.Mod Pathol. 2020; 33: 2458-2472
- Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).Mod Pathol. 2020; 33: 2186-2197
- Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.Nat Rev Endocrinol. 2017; 13: 644-660
- Overview of the 2022 WHO classification of thyroid neoplasms.Endocr Pathol. 2022; 33: 27-63
- Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy.Head Neck. 2003; 25: 662-670
- Anaplastic thyroid carcinoma: a 50-year experience at a single institution.Surgery. 2001; 130: 1028-1034
- Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases.Cancer. 1990; 66: 321-330
- American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.Thyroid. 2012; 22: 1104-1139
- Molecular-derived estimation of risk of malignancy for indeterminate thyroid cytology diagnoses.J Am Soc Cytopathol. 2020; 9: 213-220
- Probability of malignancy as determined by thyroSeq v3 genomic classifier varies according to the subtype of atypia.Cancer Cytopathol. 2022; (In press)https://doi.org/10.1002/cncy.22617
- Comparison of molecular methods and BRAF immunohistochemistry (VE1 Clone) for the detection of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis.Head Neck Pathol. 2020; 14: 1067-1079
- Immunohistochemical detection of NRAS(Q61R) protein in follicular-patterned thyroid tumors.Hum Pathol. 2016; 53: 51-57
- Detection of NTRK1/3 rearrangements in papillary thyroid carcinoma using immunohistochemistry, fluorescent in situ hybridization, and next-generation sequencing.Endocr Pathol. 2020; 31: 348-358
- Follicular thyroid neoplasms: comparison of clinicopathologic and molecular features of atypical adenomas and follicular thyroid carcinomas.Am J Surg Pathol. 2020; 44: 881-892
- Hyperplasia versus adenoma in endocrine tissues: are they different?.Trends Endocrinol Metab. 2002; 13: 23-28
- The clonality of nodules in recurrent goiters at second surgery.Langenbecks Arch Surg. 1998; 383: 453-455
- Clonality of thyroid nodules in sporadic goiter.Diagn Mol Pathol. 1995; 4: 113-121
Article info
Publication history
Published online: December 08, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
